SCHEMBL5694129

SCHEMBL5694129

CC1(C)CC2(CC(C)(C)c3ccccc32)c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 1/20 0.35
NOTUM Q6P988 2/20 0.35
KDM1A O60341 1/20 0.34
GAA P10253 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ATM Q13315 1/20 0.33
PDK2 Q15119 1/20 0.32
PDK4 Q16654 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29548964 1.00 HTR2A (0.35) HTR2ANOTUMKDM1AGAASMN1; SMN2
SCHEMBL2353102 0.86 HTR2A (0.39) HTR2ANOTUMKDM1AGAASMN1; SMN2
SCHEMBL30695310 0.86 HTR2A (0.39) HTR2ANOTUMKDM1AGAASMN1; SMN2
SCHEMBL24862270 0.84 PDK2 (0.37) SMN1; SMN2ATMPDK2
SCHEMBL18656390 0.84 RXRA (0.33) NOTUMGAASMN1; SMN2
SCHEMBL16021623 0.84 RXRA (0.33) NOTUMGAASMN1; SMN2
SCHEMBL17055594 0.82 PDK2 (0.37) HTR2AKDM1AGAASMN1; SMN2PDK2
SCHEMBL18415542 0.82 MAPT (0.39) PDK2
SCHEMBL13712348 0.81 PDK2 (0.42) GAASMN1; SMN2ATMPDK2
SCHEMBL10626686 0.80 KDM1A (0.45) HTR2AKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11530230-B2 Compound of 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-based phosphine ligand, and preparation method thereof ZHEJIANG UNIVERSITY (CN) 2022-12-20 US claimed
US-11377457-B2 3,3,3',3'-tetramethyl-1,1'-spirobiindane-based monophosphine ligand, intermediates thereof, preparation method and use of the same ZHEJIANG UNIVERSITY (CN) 2022-07-05 US claimed
CN-105229044-A Sulfonyl-containing polymeric materials with rigid and contorted divinyl crosslinkers 3M INNOVATIVE PROPERTIES CO 2016-01-06 CN claimed
CN-104662054-A Rigid and contorted divinyl crosslinkers 3M INNOVATIVE PROPERTIES CO 2015-05-27 CN claimed
EP-1660422-A2 METHOD FOR MAKING SALTS OF HYDROXY-SUBSTITUTED HYDROCARBONS GENERAL ELECTRIC COMPANY (US) 2006-05-31 EP claimed
WO-2005021477-A2 METHOD FOR MAKING SALTS OF HYDROXY-SUBSTITUTED HYDROCARBONS GENERAL ELECTRIC COMPANY (US) 2005-03-10 WO claimed
US-20250376552-A1 RESIN COMPOSITION, CURED SUBSTANCE, LAMINATE, MANUFACTURING METHOD FOR CURED SUBSTANCE, MANUFACTURING METHOD FOR LAMINATE, MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE FUJIFILM CORP (JP) 2025-12-11 US disclosed
US-20250264801-A1 RESIN COMPOSITION, CURED SUBSTANCE, LAMINATE, MANUFACTURING METHOD FOR CURED SUBSTANCE, MANUFACTURING METHOD FOR LAMINATE, MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE FUJIFILM CORPORATION (JP) 2025-08-21 US disclosed
EP-4596607-A1 RESIN COMPOSITION, CURED OBJECT, LAYERED PRODUCT, METHOD FOR PRODUCING CURED OBJECT, METHOD FOR PRODUCING LAYERED PRODUCT, METHOD FOR PRODUCING SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE FUJIFILM Corporation (JP) 2025-08-06 EP disclosed
EP-4597225-A1 FILM PRODUCTION METHOD, PHOTOSENSITIVE RESIN COMPOSITION, CURED PRODUCT PRODUCTION METHOD, CURED PRODUCT, AND LAMINATE FUJIFILM Corporation (JP) 2025-08-06 EP disclosed
EP-4596608-A1 RESIN COMPOSITION, CURED PRODUCT, LAMINATE, METHOD FOR PRODUCING CURED PRODUCT, METHOD FOR PRODUCING LAMINATE, METHOD FOR PRODUCING SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE FUJIFILM Corporation (JP) 2025-08-06 EP disclosed
US-20250236697-A1 RESIN COMPOSITION, CURED SUBSTANCE, LAMINATE, MANUFACTURING METHOD FOR CURED SUBSTANCE, MANUFACTURING METHOD FOR LAMINATE, MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE FUJIFILM CORPORATION (JP) 2025-07-24 US disclosed
US-20250230283-A1 RESIN COMPOSITION, CURED SUBSTANCE, LAMINATE, MANUFACTURING METHOD FOR CURED SUBSTANCE, MANUFACTURING METHOD FOR LAMINATE, MANUFACTURING METHOD FOR SEMICONDUCTOR DEVICE, AND SEMICONDUCTOR DEVICE FUJIFILM CORPORATION (JP) 2025-07-17 US disclosed
US-20130164518-A1 RESIN COMPOSITION FOR INJECTION COMPRISING LOW BIREFRINGENCE POLYMER BLEND, AND FRONT PANEL PREPARED USING THE SAME LG HAUSYS, LTD. (KR) 2013-06-27 US disclosed
EP-1497697-A2 PHOTORESIST COMPOSITIONS COMPRISING ACETALS AND KETALS AS SOLVENTS Clariant International Ltd. (CH) 2005-01-19 EP disclosed
WO-2003085455-A2 PHOTORESIST COMPOSITIONS COMPRISING ACETALS AND KETALS AS SOLVENTS CLARIANT INTERNATIONAL LTD (CH) 2003-10-16 WO disclosed
US-6203922-B1 GLASSY THERMOPLASTIC RESINS WITH GLASS TRANSITION TEMPERATURE THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2001-03-20 US disclosed
US-6080522-A CONTAINING PHOTORESIST AND POLYMER CLARIANT INTERNAITONAL, LTD. (CH) 2000-06-27 US disclosed
CN-1229480-A Radiation-sensitive resist composition with high heat resistance CLARIANT INT LTD (CH) 1999-09-22 CN disclosed
EP-0922998-A1 RADIATION-SENSITIVE RESIST COMPOSITION WITH HIGH HEAT RESISTANCE Clariant International Ltd. (CH) 1999-06-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11377457-B2 3,3,3',3'-tetramethyl-1,1'-spirobiindane-based monophosphine ligand, intermediates thereof, preparation method and use of the same PHOSPHO1, TPI1, TPR HTR2A 1427/4885NOTUM 1447/4885KDM1A 4585/4885
US-11530230-B2 Compound of 3,3,3′,3′-tetramethyl-1,1′-spirobiindane-based phosphine ligand, and preparation method thereof ORMDL3, TALDO1, TAC3 HTR2A 1074/4885NOTUM 903/4885KDM1A 4138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.